Lite Strategy, Inc. (LITS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.23
- As of
Kresmion compiles this page from LITS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Lite Strategy, Inc. (LITS): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-K filed 2026-09-28.
See the full LITS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LITS on one page. Preview it with sample data, then open it live with a free account.
Preview the LITS dossierActive events for LITS
- high13F: large reduction
CITADEL ADVISORS LLC cut 92% of LITS (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +108% to LITS (2026Q2)
- mediumCorporate crypto treasury
Lite Strategy, Inc. 8-K references ETH treasury activity · filed 2026-07-24
- mediumEarnings above estimates
Q1-2024: Beat consensus by 491.2% - EPS $8.46 vs $-2.1624 estimate
- mediumEarnings below estimates
Q2-2024: Missed consensus by 22.8% - EPS $-1.66 vs $-1.3515 estimate
FREE, NO ACCOUNT
Every event on LITS, as it fires
You are seeing 5 of 7 events recorded on LITS since 2026-05-26.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LITS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 55279B301 · 2026Q2 | $1.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 55279B301 · 2026Q2 | $514K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 55279B301 · 2026Q2 | $330K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LITS
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
LITS against its peers
LITS's return on equity of -170.9% ranks in the 17th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-07-31.
| Metric | LITS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 100000 | n/a | 9 |
| Operating margin | n/a | -2400.5% | n/a | 6 |
| Net margin | n/a | -923.1% | n/a | 6 |
| Return on equity | -170.9% | -74.6% | 17 | 20 |
Peers (22): CRVO, EYPT, EXOZ, QNCX, IBIO, IBO, ACET, NNVC, EDSA, BCTX, DWTX, TIL, AARD, VERU, BRNS, GRCE, GNTA, ALGS, FLNA, RNAZ, ESLA, MGX. Left out: CLCS (period gap), BSEM (no annual filing), HSTC (period gap). Fiscal periods ending between 2025-09-30 and 2026-07-31. Every figure is one full fiscal year read from one annual filing (LITS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow LITS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to LITS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.